文献速递胸部肿瘤

利美替尼(ASK120067)在局部晚期或转移性EGFR Thr790Met突变NSCLC患者中的疗效与安全性:一项多中心、单臂、2b期研究

Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
PubMed 文献 · J Thorac Oncol · 2022-06-02

该研究为在中国62家医院开展的单臂、开放标签、2b期研究,共纳入301例局部晚期或转移性EGFR T790M突变NSCLC患者,接受利美替尼160 mg每日两次口服。独立评审委员会评估的客观缓解率为68.8%(95%CI 63.2%-74.0%),疾病控制率为92.4%(95%CI 88.8%-95.1%),中位无进展生存期为11.0个月(95%CI 9.7-12.4)。

要点

  • 利美替尼160 mg每日两次口服在EGFR T790M突变NSCLC中客观缓解率达68.8%,疾病控制率92.4%。
  • 中位无进展生存期11.0个月,中位缓解持续时间11.1个月,中位总生存期未达到。
  • ≥3级治疗相关不良事件发生率为34.6%,最常见为腹泻13.0%,无治疗相关死亡。

核心结论

  • 利美替尼(ASK120067)在局部晚期或转移性EGFR T790M突变NSCLC患者中显示出有前景的疗效和可接受的安全性。

研究设计与样本

  • 单臂、开放标签、2b期研究,在中国62家医院开展。
  • 纳入局部晚期或转移性NSCLC且经中心确认肿瘤组织或血浆存在EGFR T790M突变、在一代或二代EGFR酪氨酸激酶抑制剂治疗后进展或存在原发性EGFR T790M突变的患者。
  • 患者接受利美替尼160 mg口服每日两次,直至疾病进展或不可接受的毒性。
  • 主要终点为独立评审委员会按RECIST 1.1评估的客观缓解率。
  • 2019年7月16日至2021年3月10日共301例患者入组并开始治疗,全部纳入全分析集和安全性集。

主要发现

  • 截至2021年9月9日数据截止日,76例(25.2%)仍在治疗,中位随访时间10.4个月(范围0.3-26.3)。
  • 全分析集中,独立评审委员会评估的客观缓解率为68.8%(95%CI 63.2%-74.0%),疾病控制率为92.4%(95%CI 88.8%-95.1%)。
  • 中位无进展生存期为11.0个月(95%CI 9.7-12.4),中位缓解持续时间为11.1个月(95%CI 9.6-13.8),中位总生存期未达到(95%CI 19.7个月-不可评估)。
  • 99例(32.9%)中枢神经系统转移患者的客观缓解率为64.6%(95%CI 54.4%-74.0%),中位无进展生存期为9.7个月(95%CI 5.9-11.6),中位缓解持续时间为9.6个月(95%CI 8.1-15.2)。
  • 41例可评估中枢神经系统病灶患者的确认中枢神经系统客观缓解率为56.1%(95%CI 39.7%-71.5%),中位中枢神经系统无进展生存期为10.6个月(95%CI 5.6-不可评估)。

关键数值与推荐

  • 安全性集中,289例(96.0%)发生至少1例治疗相关不良事件,最常见为腹泻(81.7%)、贫血(32.6%)、皮疹(29.9%)和厌食(28.2%)。
  • ≥3级治疗相关不良事件发生于104例(34.6%),最常见包括腹泻(13.0%)、低钾血症(4.3%)、贫血(4.0%)和皮疹(3.3%)。
  • 导致剂量中断和剂量终止的治疗相关不良事件分别发生于24.6%和2%的患者,无导致死亡的治疗相关不良事件。

临床怎么用

  • 原文结论为利美替尼在局部晚期或转移性EGFR T790M突变NSCLC患者中显示出有前景的疗效和可接受的安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limertinib (ASK120067) is a newly developed third-generation EGFR tyrosine kinase inhibitor targeting both sensitizing EGFR and EGFR Thr790Met (T790M) mutations. This study aimed to evaluate the efficacy and safety of limertinib in patients with locally advanced or metastatic EGFR T790M-mutated NSCLC. METHODS: This is a single-arm, open-label, phase 2b study conducted at 62 hospitals across the People's Republic of China. Patients with locally advanced or metastatic NSCLC with centrally confirmed EGFR T790M mutations in tumor tissue or blood plasma who progressed after first- or second-generation EGFR tyrosine kinase inhibitors or with primary EGFR T790M mutations were enrolled. Patients received limertinib 160 mg orally twice daily until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) assessed by independent review committee per the Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included disease control rate, progression-free survival (PFS), duration of response (DoR), overall survival, and safety. Safety was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03. RESULTS: From July 16, 2019, to March 10, 2021, a total of 301 patients were enrolled and started the treatment of limertinib. All patients entered the full analysis set and safety set. By the data cutoff date on September 9, 2021, 76 (25.2%) remained on treatment. The median follow-up time was 10.4 months (range: 0.3-26.3). On the basis of full analysis set, the independent review committee-assessed ORR was 68.8% (95% confidence interval [CI]: 63.2%-74.0%) and disease control rate was 92.4% (95% CI: 88.8%-95.1%). The median PFS was 11.0 months (95% CI: 9.7-12.4), median DoR was 11.1 months (95% CI: 9.6-13.8), and median OS was not reached (95% CI 19.7 months-not evaluable). Objective responses were achieved across all prespecified subgroups. For 99 patients (32.9%) with central nervous system (CNS) metastases, the ORR was 64.6% (95% CI: 54.4%-74.0%), median PFS was 9.7 months (95% CI: 5.9-11.6), and median DoR was 9.6 months (95% CI: 8.1-15.2). For 41 patients who had assessable CNS lesion, the confirmed CNS-ORR was 56.1% (95% CI: 39.7%-71.5%) and median CNS-PFS was 10.6 months (95% CI: 5.6-not evaluable). In safety set, 289 patients (96.0%) experienced at least one treatment-related adverse event (TRAE), with the most common being diarrhea (81.7%), anemia (32.6%), rash (29.9%), and anorexia (28.2%). Grade ≥3 TRAEs occurred in 104 patients (34.6%), with the most common including diarrhea (13.0%), hypokalemia (4.3%), anemia (4.0%), and rash (3.3%). TRAEs leading to dose interruption and dose discontinuation occurred in 24.6% and 2% of patients, respectively. No TRAE leading to death occurred. CONCLUSIONS: Limertinib (ASK120067) was found to have promising efficacy and an acceptable safety profile for the treatment of patients with locally advanced or metastatic EGFR T790M-mutated NSCLC. CLINICAL TRIAL INFORMATION: NCT03502850.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shi Y, Li B, Wu L, et al. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study. J Thorac Oncol. 2022. PMID: 35659581. doi:10.1016/j.jtho.2022.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。